Sanoj Punnen1, Stephen J Freedland2, Joseph C Presti3, William J Aronson4, Martha K Terris5, Christopher J Kane6, Christopher L Amling7, Peter R Carroll1, Matthew R Cooperberg8. 1. Department of Urology, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA. 2. Department of Surgery, Division of Urology, Duke University, Durham, NC, USA; Urology Section, Durham Veterans Administration Medical Center, Durham, NC, USA. 3. Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Urology Section, Department of Surgery, Veterans Administration Medical Center, Palo Alto, CA, USA. 4. Urology Section, Department of Surgery, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Urology, University of California at Los Angeles School of Medicine, Los Angeles, CA, USA. 5. Urology Section, Department of Surgery, Veterans Administration Medical Center, Augusta, GA, USA; Department of Surgery, Medical College of Georgia, Augusta, GA, USA. 6. Department of Urology, University of California, San Diego, CA, USA. 7. Department of Urology, Oregon Health Sciences University, Portland, OR, USA. 8. Department of Urology, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA, USA; Urology Section, Department of Surgery, Veterans Administration Medical Center, San Francisco, CA, USA. Electronic address: mcooperberg@urology.ucsf.edu.
Abstract
BACKGROUND: The University of California, San Francisco, Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score uses pathologic data from radical prostatectomy (RP) to predict prostate cancer recurrence and mortality. However, this clinical tool has never been validated externally. OBJECTIVE: To validate CAPRA-S in a large, multi-institutional, external database. DESIGN, SETTING, AND PARTICIPANTS: The Shared Equal Access Regional Cancer Hospital (SEARCH) database consists of 2892 men who underwent RP from 2001 to 2011. With a median follow-up of 58 mo, 2670 men (92%) had complete data to calculate a CAPRA-S score. INTERVENTION: RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The main outcome was biochemical recurrence. Performance of CAPRA-S in detecting recurrence was assessed and compared with a validated postoperative nomogram by concordance index (c-index), calibration plots, and decision curve analysis. Prediction of cancer-specific mortality was assessed by Kaplan-Meier analysis and the c-index. RESULTS AND LIMITATIONS: The mean age was 62 yr (standard deviation: 6.3), and 34.3% of men had recurrence. The 5-yr progression-free probability for those patients with a CAPRA-S score of 0-2, 3-5, and 6-10 (defining low, intermediate, and high risk) was 72%, 39%, and 17%, respectively. The CAPRA-S c-index was 0.73 in this validation set, compared with a c-index of 0.72 for the Stephenson nomogram. Although CAPRA-S was optimistic in predicting the likelihood of being free of recurrence at 5 yr, it outperformed the Stephenson nomogram on both calibration plots and decision curve analysis. The c-index for predicting cancer-specific mortality was 0.85, with the caveat that this number is based on only 61 events. CONCLUSIONS: In this external validation, the CAPRA-S score predicted recurrence and mortality after RP with a c-index >0.70. The score is an effective prognostic tool that may aid in determining the need for adjuvant therapy.
BACKGROUND: The University of California, San Francisco, Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score uses pathologic data from radical prostatectomy (RP) to predict prostate cancer recurrence and mortality. However, this clinical tool has never been validated externally. OBJECTIVE: To validate CAPRA-S in a large, multi-institutional, external database. DESIGN, SETTING, AND PARTICIPANTS: The Shared Equal Access Regional Cancer Hospital (SEARCH) database consists of 2892 men who underwent RP from 2001 to 2011. With a median follow-up of 58 mo, 2670 men (92%) had complete data to calculate a CAPRA-S score. INTERVENTION: RP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The main outcome was biochemical recurrence. Performance of CAPRA-S in detecting recurrence was assessed and compared with a validated postoperative nomogram by concordance index (c-index), calibration plots, and decision curve analysis. Prediction of cancer-specific mortality was assessed by Kaplan-Meier analysis and the c-index. RESULTS AND LIMITATIONS: The mean age was 62 yr (standard deviation: 6.3), and 34.3% of men had recurrence. The 5-yr progression-free probability for those patients with a CAPRA-S score of 0-2, 3-5, and 6-10 (defining low, intermediate, and high risk) was 72%, 39%, and 17%, respectively. The CAPRA-S c-index was 0.73 in this validation set, compared with a c-index of 0.72 for the Stephenson nomogram. Although CAPRA-S was optimistic in predicting the likelihood of being free of recurrence at 5 yr, it outperformed the Stephenson nomogram on both calibration plots and decision curve analysis. The c-index for predicting cancer-specific mortality was 0.85, with the caveat that this number is based on only 61 events. CONCLUSIONS: In this external validation, the CAPRA-S score predicted recurrence and mortality after RP with a c-index >0.70. The score is an effective prognostic tool that may aid in determining the need for adjuvant therapy.
Authors: C G Picanço-Albuquerque; C L Morais; F L F Carvalho; S B Peskoe; J L Hicks; O Ludkovski; T Vidotto; H Fedor; E Humphreys; M Han; E A Platz; A M De Marzo; D M Berman; T L Lotan; J A Squire Journal: Virchows Arch Date: 2016-02-09 Impact factor: 4.064
Authors: R Jeffrey Karnes; Voleak Choeurng; Ashley E Ross; Edward M Schaeffer; Eric A Klein; Stephen J Freedland; Nicholas Erho; Kasra Yousefi; Mandeep Takhar; Elai Davicioni; Matthew R Cooperberg; Bruce J Trock Journal: Eur Urol Date: 2017-04-08 Impact factor: 20.096
Authors: Robert B Den; Kasra Yousefi; Edouard J Trabulsi; Firas Abdollah; Voleak Choeurng; Felix Y Feng; Adam P Dicker; Costas D Lallas; Leonard G Gomella; Elai Davicioni; R Jeffrey Karnes Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Michael S Leapman; Stephen J Freedland; William J Aronson; Christopher J Kane; Martha K Terris; Kelly Walker; Christopher L Amling; Peter R Carroll; Matthew R Cooperberg Journal: J Urol Date: 2016-06-25 Impact factor: 7.450
Authors: Kamyar Ghabili; Henry S Park; James B Yu; Preston C Sprenkle; Simon P Kim; Kevin A Nguyen; Xiaomei Ma; Cary P Gross; Michael S Leapman Journal: World J Urol Date: 2020-06-19 Impact factor: 4.226
Authors: Anqi Cheng; Shanshan Zhao; Liesel M FitzGerald; Jonathan L Wright; Suzanne Kolb; R Jeffrey Karnes; Robert B Jenkins; Elai Davicioni; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; James Y Dai; Janet L Stanford Journal: Prostate Date: 2019-08-02 Impact factor: 4.104
Authors: Matthew R Cooperberg; Elai Davicioni; Anamaria Crisan; Robert B Jenkins; Mercedeh Ghadessi; R Jeffrey Karnes Journal: Eur Urol Date: 2014-07-02 Impact factor: 20.096
Authors: Ahmed S Zakaria; Russell N Schwartz; Amr Hodhod; Félix Couture; Côme Tholomier; Hanna Shahine; Cristina Negrean; David-Dan Nguyen; Marc Zanaty; Franziska Stolzenbach; Pierre I Karakiewicz; Assaad El-Hakim; Kevin C Zorn Journal: World J Urol Date: 2020-07-21 Impact factor: 4.226